Sánchez Ortega, IsabelParody, RocíoServitje Bedate, OctavioMuniesa Montserrat, CristinaArnan, MontserratPatiño, BeatrizSureda, AnnaDuarte, Rafael2018-11-292018-11-292016-06-300353-9504https://hdl.handle.net/2445/126584Aim To assess the toxicity, tolerance, steroid-sparing capacity, effectiveness, and response rate to imatinib and dasatinib for the treatment of severe sclerotic chronic graft-vs-host disease (scGVHD). Methods This retrospective study analyzed 8 consecutive patients with severe refractory scGVHD who received salvage therapy with imatinib. Patients intolerant and/or refractory to imatinib received dasatinib treatment. Results 7 patients discontinued imatinib treatment (1 achieved complete response, 5 were resistant and/or intolerant, and 1 developed grade IV neutropenia) and 1 patient achieved prolonged partial response, but died due to an infectious complication while on treatment 5 patients started dasatinib treatment (3 achieved partial responses and discontinued dasatinib, 1 achieved a durable partial response, but died due to a consecutive rapid pulmonary cGVHD progression and 1 with stable disease discontinued treatment due to gastroenteric intolerance). The response rate (partial and/or complete responses) for severe scGVHD was 25% for imatinib and 60% for dasatinib. Conclusion In our series, dasatinib was better tolerated, safer, steroid-sparing, and had a low incidence of infectious complications, which suggests that it may be a more effective therapeutic alternative for patients with refractory scGVHD than imatinib. Treatment of scGVHD with effective antifibrotic drugs such as TKI, which block the kinase fibrotic pathway, may be a safe and effective therapeutic option, but further studies are needed to confirm our findings.8 p.application/pdfengcc-by-nd (c) Sánchez Ortega, Isabel et al., 2016http://creativecommons.org/licenses/by-nd/3.0/esÚs terapèuticEfectes secundaris dels medicamentsMalalties cròniquesTherapeutic useDrug side effectsChronic diseasesinfo:eu-repo/semantics/article6670062018-11-29info:eu-repo/semantics/openAccess27374826